Zobrazeno 1 - 10
of 449
pro vyhledávání: '"Sai-Hong Ignatius Ou"'
Autor:
Michael Lopez, Garo Hagopian, Linda Doan, Benjamin J. Lee, Nathan W. Rojek, Janellen Smith, Sai-Hong Ignatius Ou, Yesim Yilmaz Demirdag, Misako Nagasaka
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 19, Iss 1, Pp 1-4 (2023)
Abstract Background Osimertinib has emerged as an important tool in the treatment of non-small cell lung cancers (NSCLC) with certain activating mutations of epidermal growth factor receptor (EGFR). However, Osimertinib may cause adverse effects, inc
Externí odkaz:
https://doaj.org/article/d654879b8c7b40eb9045464451c0236c
Autor:
Misako Nagasaka, Shannon S. Zhang, Yasmine Baca, Joanne Xiu, Jorge Nieva, Ari Vanderwalde, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Luis E. Raez, Stephen V. Liu, Sai-Hong Ignatius Ou
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Two ROS1 tyrosine kinase inhibitors have been approved for ROS1 fusion positive (ROS1+) non-small cell lung cancer (NSCLC) tumors. We performed a pan-tumor analysis of the incidence of ROS1 fusions to assess if more ROS1+ patients
Externí odkaz:
https://doaj.org/article/05a3d80854dc433ca5dd01303b8437af
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 230-237 (2023)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets to determine the frequency of ex20ins variants, and the ability of po
Externí odkaz:
https://doaj.org/article/c4da93c6b1ad420a85fa00e6dd68825d
Autor:
Sai-Hong Ignatius Ou, MD, Huamao M. Lin, PhD, MBA, Jin-Liern Hong, PhD, Yu Yin, MS, MPH, Shu Jin, MS, Jianchang Lin, PhD, Minal Mehta, MBBS, Danny Nguyen, MD, Joel W. Neal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100558- (2023)
Introduction: This study describes treatment patterns and outcomes in patients with NSCLC with EGFR exon 20 insertions (EGFRex20ins) in the United States. Methods: The Flatiron Health electronic health record database was used to select three cohorts
Externí odkaz:
https://doaj.org/article/a85d4cc4ba7e4e79b72ec1af541ad695
Autor:
Misako Nagasaka, Danielle Brazel, Yasmine Baca, Joanne Xiu, Mohammed Najeeb Al-Hallak, Chul Kim, Jorge Nieva, Jeffrey J. Swensen, David Spetzler, Wolfgang Michael Korn, Mark A. Socinski, Luis E. Raez, Balazs Halmos, Sai-Hong Ignatius Ou
Publikováno v:
Translational Oncology, Vol 36, Iss , Pp 101744- (2023)
Background: RET fusions are driver alterations in cancer and are most commonly found in non-small cell lung cancer and well-differentiated thyroid cancer. However, RET fusion have been reported in other solid tumors. Material and methods: A retrospec
Externí odkaz:
https://doaj.org/article/be4f08bbbeef4d4185ba93c951961543
Autor:
Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)
Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on
Externí odkaz:
https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82
Autor:
Jessica K. Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan S. Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-14 (2022)
Abstract Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered samples from 426,706 adult patients with solid or hematologic maligna
Externí odkaz:
https://doaj.org/article/127f5104a768437896be06715f4fd5c4
Autor:
Hui Wang, Zhi‐Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai‐Hong Ignatius Ou, Yu Yang
Publikováno v:
Cancer Medicine, Vol 11, Iss 13, Pp 2541-2549 (2022)
Abstract TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumo
Externí odkaz:
https://doaj.org/article/87d5bbdb8c0e4c029e8b501d0253d7a0
Autor:
Laura Schubert, Andrew Elliott, Anh T. Le, Adriana Estrada-Bernal, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Joshua E. Reuss, Sai-Hong Ignatius Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang Michael Korn, Wafik S. El-Deiry, Stephen V. Liu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET and NTRK gene fusions. Fusions involving the ERBB family of RTKs h
Externí odkaz:
https://doaj.org/article/70a0b6cd821d4f078b9efca4a60b1301
Autor:
Kaleem Anwar, PharmD, Lee Nguyen, PharmD, Misako Nagasaka, MD, PhD, Sai-Hong Ignatius Ou, MD, PhD, Alexandre Chan, PharmD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100452- (2023)
Introduction: Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be promising in the treatment of coronavirus disease 2019. The active antiviral component nirmatrelvir in Paxlovid is co-formulated with ritonavir, a strong c
Externí odkaz:
https://doaj.org/article/f80c0980bd8441c8a8ab68fda6612021